crohn's disease and semaglutide GLP-1 Agonists Disease: Risks and Management Semaglutide & Crohn's Disease: Safety

For patients on warfarin, INR monitoring should continue per the prescribing physician's recommendations, with potential for increased frequency during semaglutide initiation or dose changes

The injury remains sensitive

Nausea, the most common adverse effect, likely reflects GLP-1 receptor activation in brainstem areas controlling emesis

Are there non-surgical alternatives to address loose skin after weight loss

This highlights the importance of integrating sustainable dietary and activity strategies early in treatment

The effect of SGLT2 inhibitors, GLP1 agonists, and their sequential combination on cardiometabolic parameters: a randomized, prospective, intervention study